



The Women's HIV Research Collaborative honors all the women and girls who advance HIV research as scientists, advocates, and participants in studies!

Treatment & Cure

- Women with HIV are 3 times more likely to have a heart attack than women without HIV. The [REPRIEVE study](#) is exploring the prevention of heart disease among people with HIV with a goal to better understand female-specific risk factors. In 2016-2017 overall, more than 2,600 women participated in [ACTG](#) studies!
- A new **Women & HIV Cure** working group is forming in the ACTG and Women's Health Inter-Network Scientific Committee to tackle sex differences in how HIV hides in the body. **Women in science** are paving the way toward a cure!

Pre-Exposure Prophylaxis (PrEP)

- Women are giving PrEP a shot! The [HIV Prevention Trials Network \(HPTN\)](#) understands that a daily pill to prevent HIV is fantastic, but it can be challenging for some. That's why [HPTN 083](#) is enrolling transgender women (as well as cisgender men) in 7 countries around the world to test PrEP as a **long-acting injection!**
- [HPTN 084](#) is enrolling approximately **3,200** cisgender women in 7 African countries to test the same long-acting injectable as PrEP! Women are leading the way to find more HIV prevention options.

Mothers & Children

- A recent study by the [IMPAACT](#) Network led to changes in pediatric HIV treatment dosing in the US and Europe. [IMPAACT P1110](#) determined that it was **safe and effective** to give infants a daily liquid antiretroviral drug to prevent HIV acquisition.
- The [IMPAACT 2010](#) study has begun and will enroll nearly **700 pregnant women!** The study will follow these women and their infants for about a year after delivery to help determine the best treatment regimens for women with HIV and their infants.

Vaccines

- **1,565** cisgender and transgender women in the US participated in [HIV Vaccine Trials Network](#) studies recruiting women with low vulnerability to HIV from 2002-2016. That's **45%** of all US participants in these studies searching for an HIV vaccine!
- Transgender women made up **2%** of all participants in HVTN505, an HIV vaccine study that ended in 2013. Currently, transgender women make up **4%** of all participants in [AMP](#), a study of antibodies that may help to inform future HIV vaccine design.

Microbicides

- A vaginal ring for HIV prevention is currently under regulatory review. The ring slowly releases the drug dapivirine during the month it is worn. The [Microbicide Trials Network \(MTN\)](#) is also preparing to launch studies of the ring in women who are **pregnant and breastfeeding** in addition to the [REACH study](#).
- MTN's [rectal microbicide research](#) agenda evaluates HIV prevention options for people who have anal sex, including cis and trans women. Products under consideration include rectal gels, tablets, and douches.

To all the Sheroes making vital contributions to HIV research, Thank you!